BioLineRx (BLRX) Competitors $3.72 +0.06 (+1.64%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$3.73 +0.01 (+0.27%) As of 10/24/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. ESLA, INKT, NRXP, TVRD, ALGS, CUE, GNTA, ANL, OTLK, and ELYMShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), NRx Pharmaceuticals (NRXP), Tvardi Therapeutics (TVRD), Aligos Therapeutics (ALGS), Cue Biopharma (CUE), Genenta Science (GNTA), Adlai Nortye (ANL), Oncobiologics (OTLK), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Estrella Immunopharma MiNK Therapeutics NRx Pharmaceuticals Tvardi Therapeutics Aligos Therapeutics Cue Biopharma Genenta Science Adlai Nortye Oncobiologics Eliem Therapeutics BioLineRx (NASDAQ:BLRX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Which has higher earnings and valuation, BLRX or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than BioLineRx. Estrella Immunopharma is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.56-$9.22M-$8.80-0.42Estrella ImmunopharmaN/AN/AN/A-$0.30-7.93 Do analysts rate BLRX or ESLA? BioLineRx currently has a consensus price target of $26.00, suggesting a potential upside of 598.92%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 572.27%. Given BioLineRx's stronger consensus rating and higher possible upside, research analysts clearly believe BioLineRx is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, BLRX or ESLA? BioLineRx has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Do institutionals and insiders hold more shares of BLRX or ESLA? 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is BLRX or ESLA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. BioLineRx's return on equity of -49.74% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-45.34% -49.74% -17.54% Estrella Immunopharma N/A -1,132.38%-358.54% Does the media favor BLRX or ESLA? In the previous week, BioLineRx and BioLineRx both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 1.91 beat BioLineRx's score of 0.95 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment BioLineRx Positive Estrella Immunopharma Very Positive SummaryBioLineRx beats Estrella Immunopharma on 9 of the 13 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.93M$2.97B$6.23B$10.66BDividend YieldN/A57.75%5.71%4.82%P/E Ratio-0.4225.9530.2930.25Price / Sales0.56782.21595.12134.57Price / CashN/A168.3237.0161.44Price / Book0.925.6512.046.60Net Income-$9.22M$33.06M$3.32B$276.82M7 Day Performance-0.27%3.15%1.88%2.53%1 Month Performance-1.85%8.13%7.68%3.71%1 Year Performance-77.04%-2.49%56.01%33.82% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx2.2293 of 5 stars$3.72+1.6%$26.00+598.9%-76.8%$15.93M$28.94M-0.4240Analyst ForecastESLAEstrella Immunopharma3.0423 of 5 stars$1.99+13.7%$16.00+704.0%+179.7%$64.86MN/A-7.65N/ANews CoveragePositive NewsShort Interest ↓INKTMiNK Therapeutics2.8952 of 5 stars$14.77+5.5%$37.50+153.9%+106.9%$63.32MN/A-5.1330Positive NewsNRXPNRx Pharmaceuticals2.7948 of 5 stars$3.31+4.1%$34.50+942.3%+160.3%$62.99MN/A-1.482Analyst ForecastTVRDTvardi Therapeutics2.9593 of 5 stars$6.17-6.2%$55.50+799.5%N/A$61.70M$7.14M0.0080ALGSAligos Therapeutics4.0413 of 5 stars$10.44+4.5%$50.00+378.9%+7.3%$61.45M$3.94M-0.5390News CoverageAnalyst ForecastGap UpCUECue Biopharma2.4651 of 5 stars$0.82+3.1%N/A-49.7%$61.19M$9.29M-1.4760Positive NewsGap UpGNTAGenenta Science1.1557 of 5 stars$3.20+0.6%N/A+15.9%$60.82MN/A0.007News CoverageGap UpANLAdlai Nortye1.2605 of 5 stars$1.65+0.6%$9.00+445.5%-21.0%$60.52M$5M0.00127Analyst ForecastShort Interest ↑Gap UpOTLKOncobiologics2.8814 of 5 stars$1.48+13.0%$7.00+373.0%-74.0%$58.19MN/A-2.6020Positive NewsELYMEliem TherapeuticsN/A$1.93-1.0%N/A-57.2%$57.42MN/A-3.649 Related Companies and Tools Related Companies ESLA Competitors INKT Competitors NRXP Competitors TVRD Competitors ALGS Competitors CUE Competitors GNTA Competitors ANL Competitors OTLK Competitors ELYM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
